C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma (MM) and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin's lymphoma (NHL) and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below.